ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Akkermansia muciniphila-Derived Outer Membrane Vesicles as a Novel Therapeutic Approach for Mastitis: Insights From In Vitro and Vivo Studies.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes.MicrobiologyOpen · 2026Review
- Targeting the Gut-Mammary Axis for Understanding Mastitis Pathogenesis and Therapeutic Strategies.Veterinary sciences · 2025Review
- Akkermansia muciniphila-Derived Outer Membrane Vesicles as a Novel Therapeutic Approach for Mastitis: Insights From In Vitro and Vivo Studies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Mastitis is a major disease affecting the dairy industry. Although antibiotics are the most prevalent treatment for mastitis, their overuse presents significant risks to public health. Probiotic therapy has emerged as a promising alternative for controlling mastitis, but there is a lack of comprehensive studies on the efficacy and mechanisms of specific probiotics in treating this condition. Here, we investigate the potential of Akkermansia muciniphila (A. muciniphila) and its derived outer membrane vesicles (AOMVs) as therapeutic agents for mastitis. Significant differences in microbial communities were identified through an analysis of the microbiota composition in milk from healthy and mastitis cows. Spearman's correlation analysis revealed a significant negative correlation between the relative abundances of Verrucomicrobia and Akkermansia and the levels of inflammatory cytokines in mastitis milk. Furthermore, we evaluated the roles of live and pasteurized A. muciniphila in lipopolysaccharide (LPS)-induced inflammatory responses in bovine mammary epithelial cells (MAC-T). Compared to pasteurized A. muciniphila, live A. muciniphila exhibited a stronger anti-inflammatory effect, notably inhibiting the TLR4 and NF-κB signaling pathways. We also demonstrated that these effects of A. muciniphila may be mediated through AOMVs. Subsequently, the therapeutic potential of AOMVs was evaluated in vivo using an LPS-induced mastitis mouse model. The results demonstrated that AOMVs targeted the mammary glands, alleviated LPS-induced damage, and reduced inflammatory cytokine levels and signaling pathway activation. Finally, we conducted a preliminary investigation to assess the therapeutic effects of A. muciniphila on mastitis in dairy cows. Administration of A. muciniphila significantly reduced somatic cell count (SCC) in the milk of cows with mastitis. Notably, four of the five treated cows showed a decrease in SCC to below 2 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.